文献速递MDS 与骨髓增殖性肿瘤白血病

使用患者特异性诱导多能干细胞对伴非典型3q26/MECOM重排的髓系肿瘤进行建模与药物靶向研究

Modelling and drug targeting of a myeloid neoplasm with atypical 3q26/MECOM rearrangement using patient-specific iPSCs.
PubMed 文献 · Br J Haematol · 2024-08-26

本研究从携带t(3;8)(q26.2;q24)的骨髓增生异常综合征患者建立诱导多能干细胞系并分化为造血祖细胞,重现了患者MECOM表达变化及MECOM启动子和MYC血液增强子簇的H3K27ac模式。研究发现BET抑制剂通过抑制激活的MECOM对iPSC来源的MDS细胞产生凋亡效应,表明iPSC模型有助于揭示染色体结构变化所致增强子劫持机制并发现潜在治疗药物。

要点

  • 患者特异性iPSC模型可重现t(3;8)(q26.2;q24)MDS的MECOM表达变化及H3K27ac模式。
  • BET抑制剂通过抑制激活的MECOM对iPSC来源的MDS细胞产生凋亡效应。
  • iPSC模型有助于揭示增强子劫持机制并发现潜在抗癌药物候选物。

核心结论

  • 本研究证明iPSC模型可用于揭示染色体结构变化所致增强子劫持的精确机制,并发现潜在的癌症治疗药物候选物。

研究设计与样本

  • 从携带t(3;8)(q26.2;q24)的骨髓增生异常综合征患者建立诱导多能干细胞系,并分化为造血祖细胞以模拟该病的病理生理。

主要发现

  • iPSC模型重现了原代患者的MECOM表达变化以及MECOM启动子和MYC血液增强子簇(BENC)的组蛋白H3赖氨酸27乙酰化(H3K27ac)模式。
  • BET抑制剂通过抑制激活的MECOM,对iPSC来源的MDS细胞表现出凋亡效应。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Structural variations involving enhancer hijacking induce aberrant oncogene expression and cause tumorigenesis. A rare translocation, t(3;8)(q26.2;q24), is associated with MECOM and MYC rearrangement, causing myeloid neoplasms with a dismal prognosis. The most recent World Health Organization classification recognises myeloid neoplasms with MECOM rearrangement as acute myeloid leukaemia (AML) with defining genetic abnormalities. Recently, the increasing use of induced pluripotent stem cell (iPSC) technology has helped elucidate the pathogenic processes of haematological malignancies. However, its utility for investigating enhancer hijacking in myeloid neoplasms remains unclear. In this study, we generated iPSC lines from patients with myelodysplastic syndromes (MDS) harbouring t(3;8)(q26.2;q24) and differentiated them into haematopoietic progenitor cells to model the pathophysiology of MDS with t(3;8)(q26.2;q24). Our iPSC model reproduced the primary patient's MECOM expression changes and histone H3 lysine 27 acetylation (H3K27ac) patterns in the MECOM promoter and MYC blood enhancer cluster (BENC). Furthermore, we revealed the apoptotic effects of the bromodomain and extra-terminal motif (BET) inhibitor on iPSC-derived MDS cells by suppressing activated MECOM. Our study demonstrates the usefulness of iPSC models for uncovering the precise mechanism of enhancer hijacking due to chromosomal structural changes and discovering potential therapeutic drug candidates for cancer treatment.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Nakamura M, Chonabayashi K, Narita M, et al. Modelling and drug targeting of a myeloid neoplasm with atypical 3q26/MECOM rearrangement using patient-specific iPSCs. Br J Haematol. 2024. PMID: 39187468. doi:10.1111/bjh.19720

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。